Liqing Kang

Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease

Abstract Background Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of allogeneic chimeric antigen recept...